Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Neurological Diseases
Vol. 1, Issue 1, 2013May 24, 2013 EDT

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication

Christian Frois, Thomas O’Connell, Jacqueline Pesa, John Fastenau,
prior authorization access formulary preferred drug list (pdl) medicaid schizophrenia antipsychotic
Copyright Logoccby-4.0 • https://doi.org/10.36469/9853
Photo by freestocks.org on Unsplash
JHEOR
1.
Frois C, O’Connell T, Pesa J, Fastenau J. The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication. JHEOR. 2013;1(1):54-61. doi:10.36469/9853
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)

View more stats

Powered by Scholastica, the modern academic journal management system